---
title: "Sirio Pharma Co., Ltd. (300791.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300791.SZ.md"
symbol: "300791.SZ"
name: "Sirio Pharma Co., Ltd."
industry: "Personal Care Products"
datetime: "2026-05-20T16:46:18.657Z"
locales:
  - [en](https://longbridge.com/en/quote/300791.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300791.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300791.SZ.md)
---

# Sirio Pharma Co., Ltd. (300791.SZ)

## Company Overview

Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging.

| Item | Detail |
|------|--------|
| Industry | Personal Care Products |
| Exchange | CN Market |
| Website | [www.siriopharma.com](https://www.siriopharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.43)**

**Industry**: Personal Care Products

| Metric | Value |
|--------|-------|
| Industry Ranking | 21 / 28 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.33% |  |
| Net Profit YoY | -64.38% |  |
| P/B Ratio | 1.99 |  |
| Dividend Ratio | 2.75% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5581795258.86 |  |
| Revenue | 4319688634.66 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 4.25% | C |
| Profit Margin | 2.73% | C |
| Gross Margin | 32.38% | C |
| Revenue YoY | 2.33% | C |
| Net Profit YoY | -64.38% | E |
| Total Assets YoY | 1.87% | C |
| Net Assets YoY | 9.31% | B |
| Cash Flow Margin | 417.38% | A |
| OCF YoY | 2.33% | C |
| Turnover | 0.76 | B |
| Gearing Ratio | 48.12% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sirio Pharma Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.33%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.38%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.99",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.75%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5581795258.86",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4319688634.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "4.25%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "2.73%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "32.38%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "2.33%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.38%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.87%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.31%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "417.38%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "2.33%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.76",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "48.12%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 48.35 | 17/28 | 22.81 | 21.79 | 19.58 |
| PB | 2.03 | 10/28 | 3.20 | 3.06 | 2.63 |
| PS (TTM) | 1.32 | 1/28 | 1.75 | 1.68 | 1.45 |
| Dividend Yield | 2.69% | 5/28 | 2.45% | 2.15% | 2.04% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Proya (603605.SH) | A | D | A | B | C | B |
| 02 | BYHEALTH (300146.SZ) | B | C | C | A | C | B |
| 03 | BTN (300957.SZ) | B | C | B | B | C | B |
| 04 | FLYCO (603868.SH) | A | D | A | A | C | B |
| 05 | Shanghai Jahwa (600315.SH) | C | B | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-30T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Overweight | 2 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.45 |
| Highest Target | 32.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300791.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300791.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300791.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300791.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**